Naofumi Asano1,2, Akihiko Yoshida3,4, Hitoshi Ichikawa5, Taisuke Mori3, Masaya Nakamura2, Akira Kawai4,6, Nobuyoshi Hiraoka3. 1. Division of Rare Cancer Research, National Cancer Centre Research Institute, Tokyo, Japan. 2. Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan. 3. Department of Pathology and Clinical Laboratories, National Cancer Centre Hospital, Tokyo, Japan. 4. Rare Cancer Centre, National Cancer Centre Hospital, Tokyo, Japan. 5. Department of Clinical Genomics, National Cancer Centre Research Institute, Tokyo, Japan. 6. Department of Musculoskeletal Oncology, National Cancer Centre Hospital, Tokyo, Japan.
Abstract
AIMS: The diagnosis of a malignant peripheral nerve sheath tumour (MPNST) can be challenging, as the morphological criteria and existing immunohistochemical markers are not entirely specific. The recent discovery of frequent inactivation of polycomb repressive complex 2 in MPNSTs suggests that immunohistochemical detection of histone 3 trimethylated on lysine 27 (H3K27me3) could be of diagnostic help. This study aimed to clarify the utility of this marker. METHODS AND RESULTS: We performed immunostaining studies, with monoclonal (C36B11) and polyclonal antibodies in parallel. With the monoclonal antibody, 56% of 54 conventional MPNSTs showed complete loss of staining, whereas 17% showed mosaic loss and 28% showed intact staining. Three MPNSTs showed a novel geographical pattern of complete loss. All three epithelioid MPNSTs retained intact staining. Among 232 non-MPNSTs, only two (0.9%) showed complete loss of staining. Mosaic loss was observed in 38% of non-MPNSTs, whereas the remaining 61% retained intact staining. For conventional MPNSTs, complete loss of H3K27me3 was significantly associated with a higher TNM stage (P = 0.013), a deeper location (P = 0.004), and the presence of heterologous differentiation (P = 0.003). Polyclonal antibodies did not recognize 34% of cases that showed complete loss with the use of monoclonal antibodies. CONCLUSIONS: We confirmed that complete loss of H3K27me3 immunohistochemical staining is moderately sensitive and highly specific for MPNSTs. In contrast to prior studies, we found that mosaic loss of H3K27me3 staining is non-specific, and caution that such a pattern should not be considered to be diagnostic. We recommend the use of a monoclonal antibody to obtain better performance.
AIMS: The diagnosis of a malignant peripheral nerve sheath tumour (MPNST) can be challenging, as the morphological criteria and existing immunohistochemical markers are not entirely specific. The recent discovery of frequent inactivation of polycomb repressive complex 2 in MPNSTs suggests that immunohistochemical detection of histone 3 trimethylated on lysine 27 (H3K27me3) could be of diagnostic help. This study aimed to clarify the utility of this marker. METHODS AND RESULTS: We performed immunostaining studies, with monoclonal (C36B11) and polyclonal antibodies in parallel. With the monoclonal antibody, 56% of 54 conventional MPNSTs showed complete loss of staining, whereas 17% showed mosaic loss and 28% showed intact staining. Three MPNSTs showed a novel geographical pattern of complete loss. All three epithelioid MPNSTs retained intact staining. Among 232 non-MPNSTs, only two (0.9%) showed complete loss of staining. Mosaic loss was observed in 38% of non-MPNSTs, whereas the remaining 61% retained intact staining. For conventional MPNSTs, complete loss of H3K27me3 was significantly associated with a higher TNM stage (P = 0.013), a deeper location (P = 0.004), and the presence of heterologous differentiation (P = 0.003). Polyclonal antibodies did not recognize 34% of cases that showed complete loss with the use of monoclonal antibodies. CONCLUSIONS: We confirmed that complete loss of H3K27me3 immunohistochemical staining is moderately sensitive and highly specific for MPNSTs. In contrast to prior studies, we found that mosaic loss of H3K27me3 staining is non-specific, and caution that such a pattern should not be considered to be diagnostic. We recommend the use of a monoclonal antibody to obtain better performance.
Authors: Sophie Le Guellec; Nicolas Macagno; Valérie Velasco; Laurence Lamant; Marick Lae; Thomas Filleron; Nausicaa Malissen; Elisabeth Cassagnau; Philippe Terrier; Christine Chevreau; Dominique Ranchere-Vince; Jean-Michel Coindre Journal: Mod Pathol Date: 2017-07-28 Impact factor: 7.842
Authors: Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry Journal: Hum Pathol Date: 2017-05-24 Impact factor: 3.466
Authors: Inga-Marie Schaefer; Fei Dong; Elizabeth P Garcia; Christopher D M Fletcher; Vickie Y Jo Journal: Am J Surg Pathol Date: 2019-06 Impact factor: 6.394
Authors: Maria Gabriela Kuba; Bin Xu; Sandra P D'Angelo; Evan Rosenbaum; George Plitas; Dara S Ross; Edi Brogi; Cristina R Antonescu Journal: Histopathology Date: 2021-09-05 Impact factor: 5.087